AT-527

A leader in the discovery of oral direct-acting antiviral therapies joins the battle against COVID-19.

Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in a Phase 2 clinical trial in the US for the treatment of patients with moderate COVID-19 and risk factors for poor outcomes. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by markedly inhibiting replication of the SARS-CoV-2 virus.

Learn More

A network of hubs and spokes is suspended, representing the idea of a modular platform.

Our Science

The power of our purine nucleotide prodrug platform.

Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Designed with unique chemical modifications, they have the potential to enhance the safety and antiviral potency of these therapeutics.

How It Works

COVID-19

What we're up against.

COVID-19 is a severe global pandemic that continues to spread to new territories at an unprecedented rate. Medical and scientific communities are investigating the clinical manifestations of COVID-19 and the deceptive dimensions of subclinical infection with SARS-CoV-2, the virus responsible for COVID-19.

As a result, our knowledge about the disease and the virus is evolving, often in surprising ways. Stay up-to-date on the latest facts and findings from reputable sources.

About COVID-19

Global

Health Emergency

High

Transmission Rate

No

Available Vaccine

No

Oral Therapeutic*

*There is no FDA-approved, commercially available antiviral medicine for COVID-19. One investigational agent, administered intravenously, is currently available for emergency use under FDA supervision, limited to patients with severe COVID-19 illness.

News

Follow our progress.

See updates on AT-527, other antiviral therapies and company news.

May 20, 2020

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Series D financing. The financing was led by Bain Capital Life Sciences and also included new investors RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, Redmile Group, Omega Funds, and funds and accounts managed by T. Rowe Price Associates, Inc.

November 9, 2018

Atea Pharmaceuticals to present positive clinical data with AT-527 for the treatment of chronic Hepatitis C in patients with cirrhosis at The Liver Meeting^® 2018

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis.

April 12, 2018

Atea Pharmaceuticals reports positive proof of concept clinical data with AT-527 for the treatment of chronic Hepatitis C

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today reported positive data from its ongoing clinical trial of AT-527 in patients with GT-1b and GT-3 HCV infection.

All News & Press Releases